Reaction
Hypermobility Syndrome reporting signals
As of the last recalculation, Hypermobility Syndrome appears in 489 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is VALPROATE SODIUM (PRR 112.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Valproate Sodium | 49 | 112.0 | 112.3 |
| Asfotase Alfa | 10 | 43.4 | 43.4 |
| Golimumab | 58 | 32.5 | 32.5 |
| Leflunomide | 69 | 32.5 | 32.5 |
| Fentanyl | 60 | 29.4 | 29.4 |
| Certolizumab Pegol | 65 | 27.1 | 27.1 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 5 | 25.0 | 25.0 |
| Fentanyl Citrate | 10 | 24.3 | 24.3 |
| Rivastigmine | 9 | 20.7 | 20.7 |
| Hydromorphone Hydrochloride | 41 | 20.6 | 20.6 |
| Secukinumab | 61 | 18.2 | 18.2 |